Guselkumab 100 mg ( DrugBank: Guselkumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 37 | Generalised pustular psoriasis | 1 |
37. Generalised pustular psoriasis
Clinical trials : 79 / Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03998683 (ClinicalTrials.gov) | September 3, 2019 | 25/6/2019 | A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | Psoriasis | Drug: Guselkumab 100 mg;Drug: Placebo | Janssen-Cilag Ltd. | NULL | Completed | 18 Years | N/A | All | 117 | Phase 3 | France;Germany;Italy;Spain;United Kingdom |